Vogenx Inc (NASDAQ:VOGX) Stock Short Interest Jumps 93.6%

Vogenx Inc (NASDAQ:VOGX – Get Free Report) saw a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 74,122 shares, an increase of 93.6% from the October 15th total of 38,289 shares. Based on an average daily trading volume, of 80,725 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of research analysts recently commented on VOGX shares. Wall Street Zen downgraded shares of Vogenx from a “hold” rating to a “sell” rating in a report on Saturday. WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price objective on the stock. JonesTrading initiated coverage on Vogenx in a research report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective on the stock. Zacks Research upgraded Vogenx to a “hold” rating in a research report on Monday, September 28th. Finally, Weiss Ratings assumed coverage on Vogenx in a research note on Monday, November 9th. They issued a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.50.

Check Out Our Latest Report on Vogenx

Vogenx Price Performance

VOGX opened at $16.67 on Monday. The stock has a market capitalization of $247.55 million and a price-to-earnings ratio of -79.38. The company has a 50-day moving average of $22.03. Vogenx has a 1 year low of $12.95 and a 1 year high of $38.41.

Vogenx (NASDAQ:VOGX – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, research analysts predict that Vogenx will post -0.61 earnings per share for the current fiscal year.

About Vogenx

(Get Free Report)

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.

Featured Articles

Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.